Oct 01, 2021 · This is the American ICD-10-CM version of C86.4 - other international versions of ICD-10 C86.4 may differ. Applicable To Blastic plasmacytoid dendritic cell neoplasm (BPDCN) The following code (s) above C86.4 contain annotation back-references that may be applicable to C86.4 : C00-D49 Neoplasms C81-C96
Corresponding ICD-10 Codes C85.7 Other specified types of non-Hodgkin lymphoma ... Section: Blastic plasmacytoid dendritic cell neoplasm Pages: 174-177. International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020. Section: ICD-O-3.2 (2020) Morphological Codes
ICD10 codes matching "Blastic Plasmacytoid Dendritic Cell Neoplasm" Codes: = Billable. C86.4 Blastic NK-cell lymphoma
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code C86.4 are found in the index: - Lymphoma (of) (malignant) - C85.90 - blastic NK-cell - C86.4 - blastic plasmacytoid dendritic cell neoplasm (BPDCN) - C86.4; Approximate Synonyms
Rare type of hematopoietic neoplasm. Bone marrow involvement can be minimal at presentation but invariably develops with progression of disease. Following initial response to chemotherapy, relapse s invariably occur involving skin alone or associated with other site s including soft tissue and the central nervous system.
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Blastic plasma cytoid dendritic cell neoplasm is a clinically aggressive tumor derived from the precursors of plasma cytoid dendritic cell s (PDCs, also called professional type 1 interferon -producing cell s or plasma cytoid monocyte s), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination.
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
C86.4 is a billable diagnosis code used to specify a medical diagnosis of blastic nk-cell lymphoma. The code C86.4 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections.
Pain, swelling or a feeling of fullness in the abdomen. Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood.
FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C86.4 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Over 80% of patients present with skin lesions; other common sites include the bone marrow and lymph nodes. Expression of CD123 and TCF4 is required for diagnosis; in addition, most cases are positive for CD4, CD56 and TCL1.
On Wright-Giemsa preparations, the neoplastic cells are elongated with a tapered lightly basophilic agranular cytoplasm that ends with a tail shaped structure; the nucleus has blastoid features with open chromatin and a prominent nucleolus
BPDCN specific transcriptional network regulated by the E-box transcription factor TCF4 (also known as E2-2) that plays a master regulatory role in BPDCN cells and appears to be in turn regulated by the bromodomain and extraterminal domain (BET) protein BRD4 ( Cancer Cell 2016;30:764 )
Epigenetic dysregulation is very common and results from mutations in genes involved in DNA methylation, histone methylation and chromatin remodeling ( Haematologica 2019;104:729 )
Most patients are in fifth or sixth decades of life but the disease can affect any age group, including pediatric
BPDCN cells are highly dependent on BCL2 for survival ( Cancer Discov 2017;7:156 ) Neoplastic cells in BPDCN have features of nonactivation state and seem to arise in a background of immunodeficiency ( Blood Cancer J 2019;9:99 )
C. CD3. All others are typically positive in BPDCN but can also be positive in other neoplasms including acute myeloid leukemia.